Nona Biosciences Announces Licensing Agreement with the University of Alabama at Birmingham to Support B Cell Development Research
Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to I™), today announced a ...
Diffuse Large B-Cell Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive ...
Oncology Nurse Advisor2d
Ibrutinib, Acalabrutinib Have Distinct Metabolic Effects on CLL Cells
Cells treated with ibrutinib and acalabrutinib each had a unique set of 13 m/z signals, which opens up the possibility of studying these metabolites as biomarkers of therapeutic response.
Medscape2h
ACTRIMS 2025: Anticipating New Directions in Disease-Modifying Therapies for RRMS
Dr Annalisa Morgan previews discussions on disease-modifying therapies, emerging treatments such as CAR T-cell therapy, and ...
PMLiVE7d
Pfizer granted FDA approval for Adcetris combination in large B-cell lymphoma
Pfizer’s Takeda-partnered blood cancer drug Adcetris (brentuximab vedotin) has been approved by the US Food and Drug ...